{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T06:21:28Z","timestamp":1783146088798,"version":"3.54.6"},"reference-count":167,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170850"],"award-info":[{"award-number":["82170850"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012476","name":"Fundamental Research Funds for Central Universities of the Central South University","doi-asserted-by":"publisher","award":["1053320230334"],"award-info":[{"award-number":["1053320230334"]}],"id":[{"id":"10.13039\/501100012476","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Synthetic and Systems Biotechnology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.synbio.2026.04.012","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T23:59:46Z","timestamp":1777334386000},"page":"155-170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Remodeling memory T cells with chemotherapy and immune checkpoint inhibitors as host pre-conditioning to empower in vivo CAR-T therapy"],"prefix":"10.1016","volume":"14","author":[{"given":"Ding-Ya","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1402-1051","authenticated-orcid":false,"given":"Shan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.synbio.2026.04.012_bib1","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/s41409-025-02623-0","article-title":"CAR-T cell manufacturing failures and out-of-specification products in the real-world setting: a survey from the EBMT cellular therapy and immunobiology working party","volume":"60","author":"Worel","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.synbio.2026.04.012_bib2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/imm.13793","article-title":"Immunotherapy and the ovarian cancer microenvironment: exploring potential strategies for enhanced treatment efficacy","volume":"173","author":"Wang","year":"2024","journal-title":"Immunology"},{"key":"10.1016\/j.synbio.2026.04.012_bib3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41408-025-01225-9","article-title":"Risk factors for CAR T-cell manufacturing failure and patient outcomes in large B-cell lymphoma: a report from the UK national CAR T panel","volume":"15","author":"Dulobdas","year":"2025","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.synbio.2026.04.012_bib4","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s41551-026-01633-7","article-title":"Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer","volume":"10","author":"Chen","year":"2026","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.synbio.2026.04.012_bib5","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1158\/2159-8290.CD-18-1314","article-title":"Naive T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers","volume":"9","author":"Das","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.synbio.2026.04.012_bib6","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.1182\/bloodadvances.2022007057","article-title":"Real-world characteristics of T-cell apheresis and clinical response to tisagenlecleucel in B-cell lymphoma","volume":"6","author":"Cuffel","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.synbio.2026.04.012_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13092225","article-title":"Effects of chemotherapy agents on circulating leukocyte populations: potential implications for the success of CAR-T cell therapies","volume":"13","author":"Truong","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.synbio.2026.04.012_bib8","first-page":"15","article-title":"Balance cell apoptosis and pyroptosis of Caspase-3-Activating chemotherapy for better antitumor therapy","author":"Li","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.synbio.2026.04.012_bib9","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2115197","article-title":"Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sezary syndrome","volume":"11","author":"Su","year":"2022","journal-title":"OncoImmunology"},{"key":"10.1016\/j.synbio.2026.04.012_bib10","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1146\/annurev-immunol-032712-095954","article-title":"Memory T cell subsets, migration patterns, and tissue residence","volume":"31","author":"Mueller","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.synbio.2026.04.012_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113392","article-title":"Unlocking the full potential of memory T cells in adoptive T cell therapy for hematologic malignancies","volume":"144","author":"Sun","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.synbio.2026.04.012_bib12","doi-asserted-by":"crossref","DOI":"10.1172\/JCI148546","article-title":"Targeting memory T cell metabolism to improve immunity","volume":"132","author":"Corrado","year":"2022","journal-title":"J Clin Investig"},{"key":"10.1016\/j.synbio.2026.04.012_bib13","article-title":"Clinical predictive value of naive and memory T cells in advanced NSCLC","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.synbio.2026.04.012_bib14","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-2141.2010.08478.x","article-title":"Immune reconstitution in children following chemotherapy for haematological malignancies: a long-term follow-up","volume":"152","author":"van Tilburg","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.synbio.2026.04.012_bib15","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41568-023-00615-0","article-title":"Stem-like exhausted and memory CD8(+) T cells in cancer","volume":"23","author":"Gebhardt","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.synbio.2026.04.012_bib16","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jaci.2003.07.003","article-title":"Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS clinical trials group P1009 study","volume":"112","author":"Shearer","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.synbio.2026.04.012_bib17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jcyt.2014.05.019","article-title":"Cellular immunotherapy for pediatric solid tumors","volume":"17","author":"Hegde","year":"2015","journal-title":"Cytotherapy"},{"key":"10.1016\/j.synbio.2026.04.012_bib18","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/cei\/uxab038","article-title":"Reference range of naive T and T memory lymphocyte subsets in peripheral blood of healthy adult","volume":"207","author":"Xia","year":"2022","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.synbio.2026.04.012_bib19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1056\/NEJM199501193320303","article-title":"Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy","volume":"332","author":"Mackall","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.synbio.2026.04.012_bib20","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1182\/blood-2005-03-1082","article-title":"Antigen-specific T-cell memory is preserved in children treated for acute lymphoblastic leukemia","volume":"106","author":"Haining","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.synbio.2026.04.012_bib21","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/BF01789334","article-title":"Cellular immunosuppression in children with acute lymphoblastic leukemia: effect of consolidation chemotherapy","volume":"35","author":"Komada","year":"1992","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.synbio.2026.04.012_bib22","first-page":"161","article-title":"Imbalance in absolute counts of T lymphocyte subsets in patients with head and neck cancer and its relation to disease","volume":"62","author":"Kuss","year":"2005","journal-title":"Adv Otorhinolaryngol"},{"key":"10.1016\/j.synbio.2026.04.012_bib23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1479-5876-10-33","article-title":"Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes","volume":"10","author":"Milne","year":"2012","journal-title":"J Transl Med"},{"key":"10.1016\/j.synbio.2026.04.012_bib24","article-title":"Prognostic impact of absolute lymphocyte count\/absolute monocyte count ratio and prognostic score in patients with nasal-type, extranodal natural killer\/T-cell lymphoma","volume":"39","author":"Li","year":"2017","journal-title":"Tumour Biol"},{"key":"10.1016\/j.synbio.2026.04.012_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100849","article-title":"The clinical value of the changes of peripheral lymphocyte subsets absolute counts in patients with non-small cell lung cancer","volume":"13","author":"Xia","year":"2020","journal-title":"Transl Oncol"},{"key":"10.1016\/j.synbio.2026.04.012_bib26","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.3389\/fimmu.2018.01613","article-title":"Circulating T cell subpopulations correlate with immune responses at the tumor site and clinical response to PD1 inhibition in non-small cell lung cancer","volume":"9","author":"Manjarrez-Orduno","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.synbio.2026.04.012_bib27","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150807","article-title":"CAR T cell manufacturing from naive\/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome","volume":"132","author":"Arcangeli","year":"2022","journal-title":"J Clin Investig"},{"key":"10.1016\/j.synbio.2026.04.012_bib28","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13058-015-0669-x","article-title":"Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer","volume":"18","author":"Verma","year":"2016","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.synbio.2026.04.012_bib29","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1182\/blood.V84.7.2221.2221","article-title":"Lymphocyte depletion during treatment with intensive chemotherapy for cancer","volume":"84","author":"Mackall","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.synbio.2026.04.012_bib30","first-page":"18","article-title":"The effect of thymic function on immunocompetence following bone marrow transplantation","volume":"1","author":"Weinberg","year":"1995","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.synbio.2026.04.012_bib31","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1200\/JCO.2004.07.060","article-title":"Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications","volume":"22","author":"Su","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.synbio.2026.04.012_bib32","article-title":"Prior chemotherapy deteriorates T-cell quality for CAR T-cell therapy in B-cell non-hodgkin\u2019s lymphoma","volume":"13","author":"Junkuhn","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.synbio.2026.04.012_bib33","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.intimp.2009.09.008","article-title":"Doxorubicin enhances CD4(+) T-cell immune responses by inducing expression of CD40 ligand and 4-1BB","volume":"9","author":"Park","year":"2009","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.synbio.2026.04.012_bib34","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1476-4598-13-34","article-title":"CD8+T cell-specific induction of NKG2D receptor by doxorubicin plus interleukin-12 and its contribution to CD8+T cell accumulation in tumors","volume":"13","author":"Hu","year":"2014","journal-title":"Mol Cancer"},{"key":"10.1016\/j.synbio.2026.04.012_bib35","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1182\/blood.V89.10.3700","article-title":"Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy","volume":"89","author":"Mackall","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.synbio.2026.04.012_bib36","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/1042819021000029696","article-title":"Evaluation of thymic output by measurement of T-cell-receptor gene rearrangement excisional circles (TREC) in patients who have received fludarabine","volume":"44","author":"Aquino","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.synbio.2026.04.012_bib37","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1182\/blood.V90.9.3789","article-title":"Constraints on CD4 recovery postchemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells","volume":"90","author":"Hakim","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.synbio.2026.04.012_bib38","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/neuonc\/noq204","article-title":"Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme","volume":"13","author":"Fadul","year":"2011","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.synbio.2026.04.012_bib39","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00262-008-0530-5","article-title":"Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and\/or radiotherapy in breast cancer: a longitudinal study","volume":"58","author":"Mozaffari","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.synbio.2026.04.012_bib40","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.3892\/ijo_00000301","article-title":"Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy","volume":"34","author":"Bellone","year":"2009","journal-title":"Int J Oncol"},{"key":"10.1016\/j.synbio.2026.04.012_bib41","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1046\/j.1365-2567.2002.01400.x","article-title":"T-cell dynamics after high-dose chemotherapy in adults: elucidation of the elusive CD8+ subset reveals multiple homeostatic T-cell compartments with distinct implications for immune competence","volume":"106","author":"Fagnoni","year":"2002","journal-title":"Immunology"},{"key":"10.1016\/j.synbio.2026.04.012_bib42","doi-asserted-by":"crossref","first-page":"7000","DOI":"10.1158\/0008-5472.CAN-04-3792","article-title":"Recovery of CD8+ T-cell function during systemic chemotherapy in advanced ovarian cancer","volume":"65","author":"Coleman","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.synbio.2026.04.012_bib43","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00262-009-0749-9","article-title":"The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy","volume":"59","author":"Wu","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.synbio.2026.04.012_bib44","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/bjc.2012.362","article-title":"Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies","volume":"107","author":"McCoy","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.synbio.2026.04.012_bib45","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1158\/1078-0432.CCR-17-0895","article-title":"Low-Dose cyclophosphamide induces antitumor T-Cell responses, which associate with survival in metastatic colorectal cancer","volume":"23","author":"Scurr","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.synbio.2026.04.012_bib46","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317697571","article-title":"Impact of the immune cell population in peripheral blood on response and survival in patients receiving neoadjuvant chemotherapy for advanced gastric cancer","volume":"39","author":"He","year":"2017","journal-title":"Tumour Biol"},{"key":"10.1016\/j.synbio.2026.04.012_bib47","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1182\/bloodadvances.2020001797","article-title":"Lingering effects of chemotherapy on mature T cells impair proliferation","volume":"4","author":"Das","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.synbio.2026.04.012_bib48","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.7150\/jca.83615","article-title":"Tissue resident memory T cells are enriched and dysfunctional in effusion of patients with malignant tumor","volume":"14","author":"Mao","year":"2023","journal-title":"J Cancer"},{"key":"10.1016\/j.synbio.2026.04.012_bib49","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/s41588-025-02234-x","article-title":"The long-term effects of chemotherapy on normal blood cells","volume":"57","author":"Mitchell","year":"2025","journal-title":"Nat Genet"},{"key":"10.1016\/j.synbio.2026.04.012_bib50","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120974","article-title":"Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy","volume":"3","author":"Knaus","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.synbio.2026.04.012_bib51","first-page":"11","article-title":"Molecular and functional signatures associated with CAR T cell exhaustion and impaired clinical response in patients with B cell malignancies","author":"Beider","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.synbio.2026.04.012_bib52","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/pbc.20255","article-title":"Immune reconstitution after childhood acute lymphoblastic leukemia is most severely affected in the high risk group","volume":"44","author":"Ek","year":"2005","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.synbio.2026.04.012_bib53","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/bjh.18831","article-title":"Risk factors for CAR-T cell manufacturing failure among DLBCL patients: a nationwide survey in Japan","volume":"202","author":"Jo","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.synbio.2026.04.012_bib54","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1200\/JCO.23.01097","article-title":"Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-Cell lymphoma receiving chimeric antigen receptor T-Cell therapy","volume":"42","author":"Iacoboni","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.synbio.2026.04.012_bib55","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1021\/acs.nanolett.8b02321","article-title":"Engineering PD-1-Presenting platelets for cancer immunotherapy","volume":"18","author":"Zhang","year":"2018","journal-title":"Nano Lett"},{"key":"10.1016\/j.synbio.2026.04.012_bib56","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/00002371-199311000-00002","article-title":"T-cell reconstitution by molecular, phenotypic, and functional analysis in the thymus, bone marrow, spleen, and blood following split-dose polychemotherapy and therapeutic activity for metastatic breast cancer in mice","volume":"14","author":"Talmadge","year":"1993","journal-title":"J Immunother Emphas Tumor Immunol"},{"key":"10.1016\/j.synbio.2026.04.012_bib57","first-page":"280","article-title":"Thymus size and age-related thymic involution: early programming, sexual dimorphism, progenitors and Stroma","volume":"3","author":"Gui","year":"2012","journal-title":"Aging Dis"},{"key":"10.1016\/j.synbio.2026.04.012_bib58","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad5222","article-title":"Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies","volume":"8","author":"Singh","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.synbio.2026.04.012_bib59","doi-asserted-by":"crossref","DOI":"10.1002\/jha2.70040","article-title":"Prevalence of CCR7-Positive CD8 T cells as a prognostic factor in B-Cell maturation antigen -Targeted chimeric antigen receptor T cell therapy","volume":"6","author":"Marumo","year":"2025","journal-title":"EJHaem"},{"key":"10.1016\/j.synbio.2026.04.012_bib60","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10637-024-01472-w","article-title":"Clinical characteristics, treatment, and outcomes of nivolumab induced immune thrombocytopenia","volume":"42","author":"Peng","year":"2024","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.synbio.2026.04.012_bib61","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1158\/2326-6066.CIR-15-0210","article-title":"PD-1 blockade expands intratumoral memory T cells","volume":"4","author":"Ribas","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.synbio.2026.04.012_bib62","doi-asserted-by":"crossref","first-page":"21539","DOI":"10.18632\/oncotarget.15368","article-title":"Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma","volume":"8","author":"de Coana","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.synbio.2026.04.012_bib63","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s40425-018-0357-3","article-title":"Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma","volume":"6","author":"Domingo-Musibay","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.synbio.2026.04.012_bib64","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00262-022-03240-2","article-title":"The tissue-resident marker CD103 on peripheral blood T cells predicts responses to anti-PD-1 therapy in gastric cancer","volume":"72","author":"Nose","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.synbio.2026.04.012_bib65","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1186\/s12885-023-11438-5","article-title":"Significance of CD103(+) tissue-resident memory T cells for predicting the effectiveness of immune checkpoint inhibitors in esophageal cancer","volume":"23","author":"Natsuki","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.synbio.2026.04.012_bib66","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1111\/cas.13758","article-title":"Activation of central\/effector memory T cells and T-helper 1 polarization in malignant melanoma patients treated with anti-programmed death-1 antibody","volume":"109","author":"Yamaguchi","year":"2018","journal-title":"Cancer Sci"},{"key":"10.1016\/j.synbio.2026.04.012_bib67","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1007\/s11427-020-1861-5","article-title":"Peripheral CD4(+) T cell signatures in predicting the responses to anti-PD-1\/PD-L1 monotherapy for Chinese advanced non-small cell lung cancer","volume":"64","author":"Xia","year":"2021","journal-title":"Sci China Life Sci"},{"key":"10.1016\/j.synbio.2026.04.012_bib68","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.jtho.2019.04.007","article-title":"The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in Chinese patients with NSCLC","volume":"14","author":"Jin","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.synbio.2026.04.012_bib69","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2419838","article-title":"Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies","volume":"16","author":"Zhang","year":"2024","journal-title":"mAbs"},{"key":"10.1016\/j.synbio.2026.04.012_bib70","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1136045","article-title":"Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response","volume":"5","author":"Felix","year":"2016","journal-title":"OncoImmunology"},{"key":"10.1016\/j.synbio.2026.04.012_bib71","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1182\/blood.2021010867","article-title":"Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation","volume":"137","author":"Penter","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.synbio.2026.04.012_bib72","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejca.2016.12.011","article-title":"Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients","volume":"73","author":"Wistuba-Hamprecht","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.synbio.2026.04.012_bib73","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ejca.2016.12.031","article-title":"The proportion of circulating CD45RO(+)CD8(+) memory T cells is correlated with clinical response in melanoma patients treated with ipilimumab","volume":"75","author":"Tietze","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.synbio.2026.04.012_bib74","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","article-title":"Distinct immune cell populations define response to Anti-PD-1 monotherapy and Anti-PD-1\/Anti-CTLA-4 combined therapy","volume":"35","author":"Gide","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.synbio.2026.04.012_bib75","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1158\/1078-0432.CCR-22-2566","article-title":"A phase II window of opportunity study of neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 blockade for patients with malignant pleural mesothelioma","volume":"29","author":"Lee","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.synbio.2026.04.012_bib76","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41591-020-01224-2","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial","volume":"27","author":"Cascone","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.synbio.2026.04.012_bib77","first-page":"104","article-title":"Dynamic peripheral T-Cell analysis identifies On-Treatment prognostic biomarkers of Atezolizumab plus Bevacizumab in hepatocellular carcinoma","volume":"14","author":"Han","year":"2025","journal-title":"Liver Cancer"},{"key":"10.1016\/j.synbio.2026.04.012_bib78","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003392","article-title":"Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia","volume":"10","author":"Goswami","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.synbio.2026.04.012_bib79","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10549-020-05936-4","article-title":"Serial single-cell profiling analysis of metastatic TNBC during Nab-paclitaxel and pembrolizumab treatment","volume":"185","author":"Deng","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.synbio.2026.04.012_bib80","first-page":"311","article-title":"Pembrolizumab in lymphopenic metastatic breast cancer patients treated with metronomic cyclophosphamide: a clinical and translational prospective Study","volume":"15","author":"Mery","year":"2023","journal-title":"Breast Cancer"},{"key":"10.1016\/j.synbio.2026.04.012_bib81","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1186\/s12935-023-03137-9","article-title":"Circulating memory PD-1(+)CD8(+) T cells and PD-1(+)CD8(+)T\/PD-1(+)CD4(+)T cell ratio predict response and outcome to immunotherapy in advanced gastric cancer patients","volume":"23","author":"Liu","year":"2023","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.synbio.2026.04.012_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111663","article-title":"Predictive response and outcome of peripheral CD4(+) T cell subpopulations to combined immunotherapy and chemotherapy in advanced gastric cancer patients","volume":"129","author":"Gao","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.synbio.2026.04.012_bib83","doi-asserted-by":"crossref","first-page":"5621","DOI":"10.1158\/1078-0432.CCR-20-0776","article-title":"Immune activation in patients with locally advanced cervical cancer treated with ipilimumab following definitive chemoradiation (GOG-9929)","volume":"26","author":"Da Silva","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.synbio.2026.04.012_bib84","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2066609","article-title":"Evaluation of radio-immunotherapy sequence on immunological responses and clinical outcomes in patients with melanoma brain metastases (ELEKTRA)","volume":"11","author":"Hassel","year":"2022","journal-title":"OncoImmunology"},{"key":"10.1016\/j.synbio.2026.04.012_bib85","doi-asserted-by":"crossref","first-page":"7825","DOI":"10.1038\/s41467-023-43381-1","article-title":"PD-1(-) CD45RA(+) effector-memory CD8 T cells and CXCL10(+) macrophages are associated with response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma","volume":"14","author":"Cappuyns","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.synbio.2026.04.012_bib86","article-title":"Immune cell dynamics in EGFR-Mutated NSCLC treated with afatinib and pembrolizumab: results from a phase IB Study","volume":"5","author":"Riess","year":"2024","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.synbio.2026.04.012_bib87","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3389\/fimmu.2013.00020","article-title":"Role of PI3K\/Akt signaling in memory CD8 T cell differentiation","volume":"4","author":"Kim","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.synbio.2026.04.012_bib88","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.cmet.2022.03.013","article-title":"The mitochondrial pyruvate carrier regulates memory T cell differentiation and antitumor function","volume":"34","author":"Wenes","year":"2022","journal-title":"Cell Metab"},{"key":"10.1016\/j.synbio.2026.04.012_bib89","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10555-011-9273-4","article-title":"Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy","volume":"30","author":"Kepp","year":"2011","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.synbio.2026.04.012_bib90","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1182\/blood.2021012634","article-title":"Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy","volume":"139","author":"Chong","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.synbio.2026.04.012_bib91","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1182\/blood.V95.6.2024","article-title":"Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer","volume":"95","author":"Schiavoni","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.synbio.2026.04.012_bib92","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1076514","article-title":"Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes","volume":"298","author":"Dudley","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.synbio.2026.04.012_bib93","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nri2216","article-title":"Immunological aspects of cancer chemotherapy","volume":"8","author":"Zitvogel","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.synbio.2026.04.012_bib94","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004749","article-title":"Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma","volume":"4","author":"Wallen","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.synbio.2026.04.012_bib95","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1533857","article-title":"Two chemotherapeutic agents expand stem-like CD62L(+)CD8(+) T cells in antitumor immune responses","volume":"16","author":"Ruan","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.synbio.2026.04.012_bib96","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T cells in refractory antisynthetase syndrome","volume":"401","author":"Muller","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.synbio.2026.04.012_bib97","doi-asserted-by":"crossref","first-page":"6844","DOI":"10.1182\/bloodadvances.2023010364","article-title":"Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R\/R DLBCL","volume":"7","author":"Blumenberg","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.synbio.2026.04.012_bib98","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/s41556-024-01358-2","article-title":"Multimodal and spatially resolved profiling identifies distinct patterns of T cell infiltration in nodal B cell lymphoma entities","volume":"26","author":"Roider","year":"2024","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.synbio.2026.04.012_bib99","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s00281-024-01011-y","article-title":"Harnessing the tumor microenvironment to boost adoptive T cell therapy with engineered lymphocytes for solid tumors","volume":"46","author":"Spiga","year":"2024","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.synbio.2026.04.012_bib100","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1158\/1078-0432.CCR-17-0432","article-title":"Phase I study of chimeric antigen receptor-modified T cells in patients with EGFR-positive advanced biliary tract cancers","volume":"24","author":"Guo","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.synbio.2026.04.012_bib101","doi-asserted-by":"crossref","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","article-title":"Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma","volume":"118","author":"Louis","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.synbio.2026.04.012_bib102","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jcyt.2020.04.088","article-title":"Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: a phase I clinical trial","volume":"22","author":"Liu","year":"2020","journal-title":"Cytotherapy"},{"key":"10.1016\/j.synbio.2026.04.012_bib103","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000148","article-title":"Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients","volume":"8","author":"Itzhaki","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.synbio.2026.04.012_bib104","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70277","article-title":"Impact of the kinetics of circulating anti-BCMA CAR-T cells and normal lymphocytes on the outcome of MM patients","volume":"9","author":"Gutierrez-Herrero","year":"2025","journal-title":"HemaSphere"},{"key":"10.1016\/j.synbio.2026.04.012_bib105","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2025.288587","article-title":"Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed\/refractory B-cell acute lymphoblastic leukemia","author":"Jabbour","year":"2026","journal-title":"Haematologica"},{"key":"10.1016\/j.synbio.2026.04.012_bib106","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/bloodadvances.2023011287","article-title":"Timing of anti-PD-L1 antibody initiation affects efficacy\/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma","volume":"8","author":"Hirayama","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.synbio.2026.04.012_bib107","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s12916-023-02960-1","article-title":"The expression profiles of signature genes from CD103(+)LAG3(+) tumour-infiltrating lymphocyte subsets predict breast cancer survival","volume":"21","author":"Xia","year":"2023","journal-title":"BMC Med"},{"key":"10.1016\/j.synbio.2026.04.012_bib108","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.omtn.2023.03.007","article-title":"Identification of shared characteristics in tumor-infiltrating T cells across 15 cancers","volume":"32","author":"Jin","year":"2023","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.synbio.2026.04.012_bib109","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-year Follow-Up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.synbio.2026.04.012_bib110","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo","volume":"30","author":"Sommermeyer","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.synbio.2026.04.012_bib111","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.synbio.2026.04.012_bib112","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.synbio.2026.04.012_bib113","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13174279","article-title":"Clinical and product features associated with outcome of DLBCL patients to CD19-Targeted CAR T-Cell therapy","volume":"13","author":"Lamure","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.synbio.2026.04.012_bib114","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1038\/s41591-023-02496-0","article-title":"Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial","volume":"29","author":"Lin","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.synbio.2026.04.012_bib115","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1158\/1078-0432.CCR-22-2038","article-title":"Favorable activity and safety profile of memory-enriched CD19-Targeted chimeric antigen receptor T-Cell therapy in adults with high-risk Relapsed\/Refractory ALL","volume":"29","author":"Aldoss","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.synbio.2026.04.012_bib116","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1158\/2159-8290.CD-22-0964","article-title":"CD19\/CD20 bispecific Chimeric Antigen Receptor (CAR) in Naive\/Memory T cells for the treatment of relapsed or refractory non-hodgkin lymphoma","volume":"13","author":"Larson","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.synbio.2026.04.012_bib117","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.synbio.2026.04.012_bib118","doi-asserted-by":"crossref","first-page":"5737","DOI":"10.1182\/bloodadvances.2021006293","article-title":"Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL","volume":"6","author":"Talleur","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.synbio.2026.04.012_bib119","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.synbio.2026.04.012_bib120","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1158\/1078-0432.CCR-22-0164","article-title":"Phenotypic composition of commercial Anti-CD19 CAR T cells affects in vivo expansion and disease response in patients with large B-cell lymphoma","volume":"28","author":"Monfrini","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.synbio.2026.04.012_bib121","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","article-title":"Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15","volume":"123","author":"Xu","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.synbio.2026.04.012_bib122","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc3196","article-title":"A subset of cytotoxic effector memory T cells enhances CAR T cell efficacy in a model of pancreatic ductal adenocarcinoma","volume":"13","author":"Konduri","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.synbio.2026.04.012_bib123","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.omtm.2021.06.014","article-title":"Depletion of high-content CD14(+) cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing","volume":"22","author":"Wang","year":"2021","journal-title":"Mol Ther, Methods Clin Dev"},{"key":"10.1016\/j.synbio.2026.04.012_bib124","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/bloodadvances.2019000600","article-title":"T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma","volume":"3","author":"Garfall","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.synbio.2026.04.012_bib125","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jcyt.2021.07.015","article-title":"Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: time for a collect-and-freeze model?","volume":"23","author":"Palen","year":"2021","journal-title":"Cytotherapy"},{"key":"10.1016\/j.synbio.2026.04.012_bib126","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","article-title":"Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL","volume":"609","author":"Zhang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.synbio.2026.04.012_bib127","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/bjh.18816","article-title":"Early lymphocyte collection for anti-CD19 CART production improves T-cell fitness in patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"202","author":"Dubnikov Sharon","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.synbio.2026.04.012_bib128","doi-asserted-by":"crossref","DOI":"10.1111\/sji.13352","article-title":"Predictive model for CAR-T cell therapy success in patients with relapsed\/refractory B-cell acute lymphoblastic leukaemia","volume":"99","author":"Pu","year":"2024","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.synbio.2026.04.012_bib129","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41392-023-01659-2","article-title":"Characteristics of premanufacture CD8(+)T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphoma","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.synbio.2026.04.012_bib130","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/nm.2446","article-title":"A human memory T cell subset with stem cell-like properties","volume":"17","author":"Gattinoni","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.synbio.2026.04.012_bib131","first-page":"594","article-title":"Superior T memory stem cell persistence supports long-lived T cell memory","volume":"123","author":"Lugli","year":"2013","journal-title":"J Clin Investig"},{"key":"10.1016\/j.synbio.2026.04.012_bib132","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/44385","article-title":"Two subsets of memory T lymphocytes with distinct homing potentials and effector functions","volume":"401","author":"Sallusto","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.synbio.2026.04.012_bib133","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101663","article-title":"GD2 CAR-T cells in combination with Nivolumab exhibit enhanced antitumor efficacy","volume":"32","author":"Zhang","year":"2023","journal-title":"Transl Oncol"},{"key":"10.1016\/j.synbio.2026.04.012_bib134","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1056\/NEJMc2509522","article-title":"In vivo CD19 CAR T-Cell therapy for refractory systemic lupus erythematosus","volume":"393","author":"Wang","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.synbio.2026.04.012_bib135","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1183698","article-title":"CD62L as target receptor for specific gene delivery into less differentiated human T lymphocytes","volume":"14","author":"Kapitza","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.synbio.2026.04.012_bib136","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.immuni.2013.08.010","article-title":"Cell-intrinsic IL-27 and gp130 cytokine receptor signaling regulates virus-specific CD4(+) T cell responses and viral control during chronic infection","volume":"39","author":"Harker","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.synbio.2026.04.012_bib137","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.3324\/haematol.2021.280189","article-title":"Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies","volume":"107","author":"Dos Santos","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.synbio.2026.04.012_bib138","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"CAR-T cell therapy for cancer: current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.synbio.2026.04.012_bib139","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.7150\/ijbs.34213","article-title":"Current progress in CAR-T cell therapy for solid tumors","volume":"15","author":"Ma","year":"2019","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.synbio.2026.04.012_bib140","article-title":"CAR-T cell therapy in hematological malignancies: current opportunities and challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.synbio.2026.04.012_bib141","article-title":"In vivo production of CAR T cell: opportunities and challenges","volume":"12","author":"Song","year":"2025","journal-title":"Genes Dis"},{"key":"10.1016\/j.synbio.2026.04.012_bib142","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105266","article-title":"Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment","volume":"106","author":"Bui","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.synbio.2026.04.012_bib143","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/17425247.2025.2452295","article-title":"Roadmap to discovery and early development of an mRNA loaded LNP formulation for liver therapeutic genome editing","volume":"22","author":"Bak","year":"2025","journal-title":"Expet Opin Drug Deliv"},{"key":"10.1016\/j.synbio.2026.04.012_bib144","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41573-025-01291-5","article-title":"In vivo chimeric antigen receptor (CAR)-T cell therapy","volume":"25","author":"Bot","year":"2026","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.synbio.2026.04.012_bib145","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s40164-025-00725-5","article-title":"In vivo CAR-T cell engineering: concept, research progress, potential challenges and enhancement strategies","volume":"14","author":"Chen","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.synbio.2026.04.012_bib146","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13045-025-01759-2","article-title":"In vivo CAR cell therapy: from bench to bedside","volume":"18","author":"Xu","year":"2025","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.synbio.2026.04.012_bib147","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1016\/j.ymthe.2022.05.018","article-title":"Precision medicine: in vivo CAR therapy as a showcase for receptor-targeted vector platforms","volume":"30","author":"Michels","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.synbio.2026.04.012_bib148","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114379","article-title":"In vivo nano-engineering T cells for CAR-T therapy","volume":"388","author":"Shi","year":"2025","journal-title":"J Control Release"},{"key":"10.1016\/j.synbio.2026.04.012_bib149","doi-asserted-by":"crossref","first-page":"eadx0368","DOI":"10.1126\/scitranslmed.adx0368","article-title":"Anti-FAP CAR T cells produced in vivo reduce fibrosis and restore liver homeostasis in metabolic dysfunction-associated steatohepatitis","volume":"18","author":"Yashaswini","year":"2026","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.synbio.2026.04.012_bib150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2026.02.020","article-title":"Reprogramming CD22 CAR-T cells in vivo using CD8-targeted mRNA-LNPs to treat hematological malignancies","author":"Lemgart","year":"2026","journal-title":"Mol Ther"},{"key":"10.1016\/j.synbio.2026.04.012_bib151","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1158\/1535-7163.MCT-17-1097","article-title":"Strategies to address chimeric antigen receptor tonic signaling","volume":"17","author":"Ajina","year":"2018","journal-title":"Mol Cancer Therapeut"},{"key":"10.1016\/j.synbio.2026.04.012_bib152","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2020.188386","article-title":"Priming the tumor immune microenvironment with chemo(radio)therapy: a systematic review across tumor types","volume":"1874","author":"van den Ende","year":"2020","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.synbio.2026.04.012_bib153","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.577869","article-title":"Immunotherapy for ovarian cancer: adjuvant, combination, and neoadjuvant","volume":"11","author":"Yang","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.synbio.2026.04.012_bib154","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3389\/fcell.2020.00803","article-title":"Augmenting the effectiveness of CAR-T cells by enhanced self-delivery of PD-1-Neutralizing scFv","volume":"8","author":"Ping","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.synbio.2026.04.012_bib155","doi-asserted-by":"crossref","first-page":"8893","DOI":"10.2147\/CMAR.S260915","article-title":"EGLIF-CAR-T cells secreting PD-1 blocking antibodies significantly mediate the elimination of gastric cancer","volume":"12","author":"Zhou","year":"2020","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.synbio.2026.04.012_bib156","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008429","article-title":"PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion","volume":"12","author":"Ouyang","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.synbio.2026.04.012_bib157","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1172\/JCI40269","article-title":"Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice","volume":"120","author":"Ramakrishnan","year":"2010","journal-title":"J Clin Investig"},{"key":"10.1016\/j.synbio.2026.04.012_bib158","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1158\/0008-5472.CAN-13-1545","article-title":"Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer","volume":"74","author":"Alizadeh","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.synbio.2026.04.012_bib159","doi-asserted-by":"crossref","first-page":"6761","DOI":"10.1158\/1078-0432.CCR-21-0998","article-title":"Neoadjuvant FOLFIRINOX therapy is associated with increased effector T cells and reduced suppressor cells in patients with pancreatic cancer","volume":"27","author":"Peng","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.synbio.2026.04.012_bib160","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/mt.2016.63","article-title":"GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade","volume":"24","author":"Gargett","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.synbio.2026.04.012_bib161","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.omto.2016.11.005","article-title":"Enhancement of PSMA-Directed CAR adoptive immunotherapy by PD-1\/PD-L1 blockade","volume":"4","author":"Serganova","year":"2017","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.synbio.2026.04.012_bib162","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/mc.23202","article-title":"Central memory phenotype drives success of checkpoint inhibition in combination with CAR T cells","volume":"59","author":"Toews","year":"2020","journal-title":"Mol Carcinog"},{"key":"10.1016\/j.synbio.2026.04.012_bib163","doi-asserted-by":"crossref","DOI":"10.4028\/b-XDTcg5","article-title":"Targeting of the CD161 inhibitory receptor enhances bone-marrow-resident memory CD8(+) T-Cell-Mediated immunity against multiple myeloma","author":"Wang","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.synbio.2026.04.012_bib164","doi-asserted-by":"crossref","DOI":"10.1172\/JCI184043","article-title":"Targeting immune checkpoint LAIR1 with antibody blockade or 3-in-1 CAR T cells enhances antitumor response","volume":"135","author":"Tao","year":"2025","journal-title":"J Clin Investig"},{"key":"10.1016\/j.synbio.2026.04.012_bib165","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.ccell.2022.08.008","article-title":"High-performance multiplex drug-gated CAR circuits","volume":"40","author":"Li","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.synbio.2026.04.012_bib166","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.synbio.2026.04.012_bib167","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1016\/j.ymthe.2023.09.021","article-title":"Arming CAR-T cells with cytokines and more: innovations in the fourth-generation CAR-T development","volume":"31","author":"Tang","year":"2023","journal-title":"Mol Ther"}],"container-title":["Synthetic and Systems Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405805X26001043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405805X26001043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T06:07:46Z","timestamp":1783145266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405805X26001043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":167,"alternative-id":["S2405805X26001043"],"URL":"https:\/\/doi.org\/10.1016\/j.synbio.2026.04.012","relation":{},"ISSN":["2405-805X"],"issn-type":[{"value":"2405-805X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Remodeling memory T cells with chemotherapy and immune checkpoint inhibitors as host pre-conditioning to empower in vivo CAR-T therapy","name":"articletitle","label":"Article Title"},{"value":"Synthetic and Systems Biotechnology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.synbio.2026.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.","name":"copyright","label":"Copyright"}]}}